Online Payments : Service Charges on Digital Payments Withdrawn

The Union Cabinet has approved a proposal to withdraw the surcharge/service charge or convenience fee on digital payments. The directive will apply to all kinds of digital payments like credit/debit cards, pre-paid cards, mobile payments or mobile wallet payments for any government service.Many retail stores and merchants charge an additional surcharge in case of non-cash payments. 

User

Banking : India Post To Allow Bank Customers To Use Its ATMs

India Post has received a licence for starting a payments bank. It will send a proposal to the Reserve Bank of India (RBI) to allow ATMs of India Post to work on the platforms of all other banks. Currently, about 600 ATMs have been installed across the country; the target is to take this number to 1,000 by end-March 2016 and 10,000 in the next couple of years. Also, 20,000 micro-ATMs will be set up in the same period. 

User

Pfizer falls 9% after withdrawing Corex from India
Pfizer says it stopped manufacture and sale of its cough syrup Corex in India, which recorded a sale of Rs176 crore for first three quarters of FY2016
 
Pharmaceutical company Pfizer said it has decided to stop producing and selling its cough syrup Corex in India. This follows direction from the Indian government prohibiting the company from selling fixed dose combination of Chlopheniramine Maleate and Codeine Syrup. Following the announcement, the company shares ended 9% down to Rs1,760 on the BSE.
 
In a regulatory filing, Pfizer said, "... the Government of India vide notification no SO 909(E) dated 10 March 2016 has prohibited the manufacture for sale, sale and distribution of fixed dose combination of Chlopheniramine Maleate and Codeine Syrup with immediate effect. In view of this, the Company has discontinued the manufacture and sale of its drug Corex with immediate effect."
 
"The above prohibition is likely to have an adverse impact on the revenues and profitability of the Company. It may be noted that Corex recorded a sale of Rs176 crore for the nine months ended 31 December 2015," Pfizer added.
 
Meanwhile, the Delhi High Court on Monday granted interim stay of notification restraining sale of pharma major Pfizer’s cough syrup ‘Corex’ and directed the government not to take coercive steps against the company. The court’s order came on a plea moved by Pfizer who contended that no show cause notice or hearing was granted prior to the notification.
 
Pfizer opened Monday at Rs1,890, its high for the day. However, soon after it started to fall to touch Rs1,753 toward the end of the trading. But it managed to recover and close at Rs1760.80, still 8.67% down from previous close.   
 
Pfizer ended Monday about 9% down at Rs1,760 on the BSE, while the benchmark Sensex closed marginally higher at 24,804.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)